Welcome!

News Feed Item

Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies

NEW YORK, March 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies

http://www.reportlinker.com/p02041940/Drug-Discovery-Outsourcing-World-Market-Forecast-2014-2024--Future-Prospects-for-Leading-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Report Details

Drug discovery outsourcing - discover trends and segments with highest revenue potential

What does the future hold for drug discovery outsourcing? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our new study is your guide to the potential of those pharmaceutical services. It lets you assess projected sales at world market, submarket and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions.

In our investigation you also see qualitative analyses, new R&D and business developments. Our 194 page report provides 152 tables, charts, and graphs. Read the full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

- Dr. Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience, Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium

- Dr. Mark Craighead, Director of Scientific Strategy, Redx Pharma

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of four outsourcing submarkets at world level to 2024:

• Chemical services

• Biological services

• Lead optimisation

• Lead identification and screening

With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can win competitive advantages by understanding the trends, opportunities and challenges facing contract research organisations (CROs) in drug discovery.

What are the prospects in leading regions and countries?

Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. There are many opportunities for CRO service providers and pharma clients.

In our study you will find individual revenue forecasts to 2024 for 12 national markets:• US• Japan• UK• Germany• France• Spain• Italy• China• India• Brazil• Russia• South Korea• RoW

Emerging economies have large, highly educated workforces and competitive price regimes. Therefore countries like China and India continue to rapidly emerge as important outsourcing destinations for research and manufacturing.

Greater uptake of existing technology worldwide will also stimulate the industry and market.

Leading companies and potential for market growth

Overall world revenue for that market area will reach $14.9bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what services and organisations hold greatest potential. See profiles of 13 leading companies, including these:

• Albany Molecular Research (AMRI)

• Aptuit

• Charles River Laboratories

• Covance

• Cyprotex

• Domainex

• Evotec

• Galapagos

• GenScript

• Pharmaceutical Product Development (PPD)

• Quintiles

• WIL Research Laboratories

• WuXi AppTec

In general, a company profile gives you the following information• Discussion of a company's activities and outlook• Recent financial results• Assessment of recent developments - mergers and acquisitions (M&A) and collaborations.• Drug discovery revenue forecasts to 2024

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect outsourced drug discovery?

Our new report discusses issues and events affecting early-stage drug development. You will find discussions, including qualitative analyses:

• Increasing focus on biologic drugs continues to provide CROs with expansion opportunities

• Changing R&D models in the pharmaceutical industry

• Progress in target identification, validation, chemistry, biology and ADMET screening

• Emerging markets offering reprieve from the effects of cost pressures and declining R&D budgets

Also, you find coverage of these aspects:• Regional expansion, competition and CRO consolidation• Niche CROs and virtual pharmaceutical companies• Technology transfer and intellectual property (IP)• Competition from private-public partnerships

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies report helps you

In summary, our 194 page report gives you the following knowledge:

• Revenues forecasts to 2024 for the overall world drug discovery outsourcing market and 4 submarkets - discover the industry's prospects, finding promising places for investments and revenues

• Assessment of 13 leading companies, and others, discovering activities and outlooks

• Market forecasting to 2024 for 12 national markets - US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India, China, South Korea and RoW.

• View opinions from our survey, seeing interviews with authorities

• Investigation of competition and opportunities influencing sales

• Discussion of what stimulates and restrains the industry and market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

1. Executive Summary

1.1 Market Highlights

1.2 Overview of the Report Content

1.3 Research and Analysis Methods

1.4 Glossary of Terms Related to Drug Discovery Outsourcing

2. An introduction to Drug Discovery Outsourcing

2.1 What is Outsourcing?

2.1.1 Drug Discovery Outsourcing: Forming Global Networks

2.2 Why Outsource Drug Discovery?

2.2.1 The Move from Tactical to Strategic Outsourcing

2.2.2 The Advantages of Drug Discovery Outsourcing

2.2.3 Technological Advances Making In-House Drug Development Unsustainable

2.2.4 Emerging Markets Offering Reprieve from the Effects of Cost Pressures and Declining

R&D Budgets

2.2.5 Strategic Partnerships: A Prequel to CRO Acquisition

2.2.6 Outsourcing to Improve Efficiency and Reduce Time-to-Market

2.3 Typically Outsourced Processes in Drug Discovery

2.4 A Paradigm Shift for Drug Development

2.4.1 Collaboration with Academia is Key for Pipeline Replenishment

2.5 Quality of Service is Integral for CRO Growth

2.6 Outsourcing: Reducing the Cost of Innovation

3. Global Drug Discovery Outsourcing Market 2014-2024

3.1 Drug Discovery Outsourcing: Global Market Overview

3.1.1 The Global Drug Discovery Outsourcing Market in 2012 and 2013

3.2 Global Drug Discovery Outsourcing: Market Forecast 2014-2024

3.2.1 Changing Market Shares by Sector 2014-2024

3.3 Global Chemistry Services Outsourcing Market 2014-2024

3.3.1 The Global Chemistry Services Outsourcing Market in 2012 and 2013

3.3.1.1 Libraries: Important for Cost Reduction and Time Efficiency

3.3.1.2 Custom Synthesis: A Major Driver for Long-Term Strategic Partnerships

3.3.1.3 Building Blocks: Promotes Efficiency of Drug Synthesis

3.3.2 Global Chemistry Services Outsourcing Forecast 2014-2024

3.4 Global Biology Services Outsourcing Market 2014-2024

3.4.1 The Global Biology Services Outsourcing Market in 2012 and 2013

3.4.1.1 Target Identification

3.4.1.2 Target Validation

3.4.2 Global Biology Services Outsourcing Forecast 2014-2024

3.5 Global Lead Optimization Market 2014-2024

3.5.1 The Global Lead Optimization Market in 2012 and 2013

3.5.1.1 ADMET Screening: To Prevent Late Stage Failure of Clinical Trials

3.5.2 Global Lead Optimisation Forecast 2014-2024

3.6 Global Lead Identification and Screening Outsourcing Market 2014-2024

3.6.1 The Global Lead Identification and Screening Outsourcing Market in 2012 and 2013

3.6.1.1 Methodologies of Lead Identification

3.6.2 Global Lead Identification and Screening Outsourcing Market: Forecast 2014-2024

4. Leading National Markets 2014-2024

4.1 Drug Discover Outsourcing - A Game of Supply versus Demand

4.1.1 The Global Distribution of Drug Discovery Outsourcing in 2012 and 2013

4.2 Leading National Markets: Forecast 2014-2024

4.2.1 Changing Market Shares by Region 2014-2024

4.3 Regional Drug Discovery Outsourcing Markets: Analysis and Forecasts 2014-2024

4.3.1 United States: Patent Expiries Boosting Pipeline Investment

4.3.2 The EU5 Markets

4.3.2.1 EU5: Changing Market Shares by Country 2014-2024

4.3.2.2 Germany: Europe's Largest Drug Discovery Outsourcing Market

4.3.2.3 UK: A Service-Oriented Market

4.3.2.4 France: Market Dominated by Large CROs

4.3.2.5 Italy: Heavy Investment from Multinational CROs will Drive Growth

4.3.2.6 Spain: An Immature Market with Potential

4.3.3 Japan: An Aging Population Putting a Strain on Pharma

4.3.4 The BRIC Nations: Rapid Growth will Fuel the Global Market

4.3.4.1 China: Rapid Market Expansion Fuelled by Acquisitions

4.3.4.2 India: R&D Infrastructure Needed for Market Boom

4.3.4.3 Brazil: The Largest Pharma Market in Latin America

4.3.4.4 Russia: A Highly Fragmented Market

4.3.5 South Korea: A Pharmaceutical Powerhouse of the Future

5. Leading Companies Offering Drug Discovery Services

5.1 Drug Discovery Outsourcing: An Expanding Marketplace

5.2 What Makes a Successful Contract Research Organisation?

5.2.1 A Business Model that Encourages Cost Reduction

5.2.2 A Workforce with Proven Expertise

5.2.3 Good Working Relationship: A Requisite for Outsourcing

5.2.4 Adequate Intellectual Property Protection

5.2.5 Huge Emphasis is placed on Communication and Timeliness

5.3 Leading Companies in the Drug Discovery Outsourcing Arena

5.4 Albany Molecular Research (AMRI)

5.4.1 SMARTSOURCING for Enhanced Decision-Making

5.4.2 AMRI's Drug Discovery Services

5.4.3 AMRI's Licensing Agreements and Drug Discovery Collaborations

5.4.4 AMRI Revenue Forecast 2014-2024

5.5 Aptuit

5.5.1 INDIGO: Aptuit's Accelerated Drug Development Programme

5.5.2 Strategic Partnerships Strengthening Aptuit's Outlook

5.6 Charles River Laboratories

5.6.1 Charles River: Strong Sales of Research Models Boosts Revenue

5.6.2 Charles Rivers: Corporate Restructuring to Maximise Efficiency

5.6.3 Charles River: Revenue Analysis and Forecast 2014-2024

5.7 Covance

5.7.1 Refocusing Early-Stage Efforts

5.7.2 Covance Strategic Partnerships

5.7.3 Covance: Revenue Analysis and Forecast 2014-2024

5.8 Cyprotex: An ADME-Tox Service Provider

5.8.1 Cyprotex: Revenue Analysis and Forecast 2014-2024

5.9 Domainex: Pipeline Products Showing Promise

5.10 Evotec: Discovery Alliances and Development Partnerships

5.10.1 Action Plan 2016 - Leadership in Drug Discovery Solutions

5.10.2 Evotec: Revenue Analysis and Forecast 2014-2024

5.11 Galapagos

5.11.1 Galapagos - Recent Activity

5.12 GenScript: A Biology-Focused Research Company

5.12.1 GenScript: Agreements and Partnerships

5.13 Pharmaceutical Product Development (PPD): A Leading CRO

5.13.1 PPD: Agreements, Strategic Partnerships and Private Merger

5.13.2 PPD's Expansion in the Asian Markets

5.13.3 PPD and BioDuro: A Key Acquisition for Chinese Market Dominance

5.14 Quintiles: The World's Largest Biopharmaceutical Services Company

5.14.1 Quintiles: Acquisition of Advion Bioanalytical Labs

5.14.2 Quintiles - New Developments

5.14.3 Quintiles: Revenue Analysis and Forecast 2014-2024

5.15 WIL Research Laboratories

5.16 WuXi AppTec: China's Leading CRO

5.16.1 WuXi AppTec: Revenue Analysis, 2008-2012

5.16.2 WuXi's Strategic Partnerships and Recent Developments

5.16.3 WuXi AppTec: Revenue Forecast 2014-2024

6. Drug Discovery Outsourcing Market: Analysis and Trends

6.1 SWOT Analysis of the Drug Discovery Outsourcing Market 2014-2024

6.2 Strengths

6.2.1 Cost Reduction: A Central Driver for Outsourcing

6.2.2 Efficient Turnaround Times is Key for the Growth of Outsourcing

6.2.3 Acquisitions and Mergers allows for a more Comprehensive Service Provision

6.3 Weaknesses

6.3.1 The Negative Effects of Falling R&D Spending

6.3.2 Market Saturation and Poorly-Defined Service Offerings

6.4 Opportunities

6.4.1 The Available Scope for the Expansion of CROs

6.4.2 Targeted Therapies: Advances in Biologics and Orphan Drugs

6.4.3 Orphan Drug Development: An Opportunity for Higher Premiums

6.4.4 The Rise of Biologics and Biosimilars

6.4.5 The Multi-directional Expansion of CROs

6.4.6 The Rise of Virtual Pharma Companies

6.5 Threats

6.5.1 A Competitive Market Causing Smaller CROs to Miss Out

6.5.2 Private-Public Alliances May Become a Threat to Drug Discovery Outsourcing

6.5.3 Intellectual Property Leaks and the Challenges of Technology Transfer

6.5.4 Resource Sharing by Pharma Companies Could Restrain CRO Growth

6.6 Porter's Five Force Analysis of the Drug Discovery Outsourcing Market

6.6.1 Power of Suppliers: Medium

6.6.2 Threat of Substitutes: Medium

6.6.3 Rivalry among Competitors: High

6.6.4 Bargaining Power of Buyers: High

6.6.5 Threat of New Entrants: Medium

7. Expert Opinions

7.1 Interview with Dr Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience at Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium

7.1.1 Current State of the Drug Discovery Outsourcing Industry

7.1.2 Drug Discovery Collaborations between Pharma and Academia

7.1.3 Academic Research: A Restraint to CRO Growth?

7.1.4 The Changing Outsourcing Model: Implications for Pharma R&D

7.1.5 The Move towards Shared Risk Partnerships

7.1.6 Hot Therapeutic Areas in Drug Discovery

7.1.7 Views on the Future Prospects of the Market

7.2 Interview with Dr Mark Craighead, Director of Scientific Strategy, Redx Pharma

7.2.1 Changes in the Industry's Pricing Model

7.2.2 Redx Pharma's Services and Growth Plans

7.2.3 Is Outsourcing Earlier the Key to Solving Pharma's R&D Problems?

7.2.4 Appealing Therapeutic Areas and the Role of the Asian Markets

8. Conclusion

8.1 Market Overview

8.2 A Move towards Biology Services

8.3 The Rise of the Asian Outsourcing Industry

8.4 Unmet Therapeutic needs will Stimulate Drug Discovery Drive

8.5 Alliances and Collaborations Will Continue to Dominate the Market

List of Tables

Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2013

Table 2.2 Selected Drug Discovery Outsourcing Alliances 2012- 2013

Table 2.3 Selected Drug Discovery Outsourcing Alliances 2009- 2012

Table 3.1 PhRMA's Historical Estimate for its Member's R&D Spending ($bn)

Table 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn), Market Shares (%) and Growth (%) by Sector, 2012 and 2013

Table 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%) by Sector, 2012-2017

Table 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2017-2024

Table 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017, 2017-2024, and 2012-2024

Table 3.6 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2024

Table 3.7 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2024

Table 3.8 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 3.9 The Biology Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 3.10 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 3.11 Selected Drug Discovery Lead Optimisation Partnerships

Table 3.12 Selected Methods for Sourcing Lead Compounds, 2013

Table 3.13 The Global Lead Identification and Screening Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) and Growth (%) by Region, 2012 and 2013

Table 4.2 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2012-2017

Table 4.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2017-2024

Table 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017, 2017-2024, and 2012-2024

Table 4.5 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012, 2017, 2024

Table 4.6 The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.7 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 4.8 The EU5 Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Market Share (%) and CAGR (%), 2012-2024

Table 4.9 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by Country, 2012-2017

Table 4.10 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by Country, 2017-2024

Table 4.11 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 2012-2017, 2017-2024, and 2012-2024

Table 4.12 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012, 2017, 2024

Table 4.13 The German Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024

Table 4.15 The UK Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.16 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024

Table 4.17 The French Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.18 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,

CAGR%), 2012-2024

Table 4.19 The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.20 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024

Table 4.21 The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.22 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024

Table 4.23 The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.24 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 4.25 The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.26 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 4.27 The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.28 The Indian Population: Demographic Forecast by Age Group (%), 2015, 2020, 2025

Table 4.29 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,

CAGR%), 2012-2024

Table 4.30 The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.31 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 4.32 The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.33 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 4.34 The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market Share (%) and CAGR (%), 2012-2024

Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2024

Table 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m, AGR %), 2008-2012

Table 5.2 AMRI: Services offered and Descriptions, 2013

Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage

Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.5 Aptuit: Services Offered and their Descriptions, 2013

Table 5.6 Charles River Laboratories: Selected Services Provided, 2013

Table 5.7 Charles River: Historical Revenue ($m, AGR %), 2010-2012

Table 5.8 Charles River: Historical Revenue ($m) by Segment, 2009-2012

Table 5.9 Charles River: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.10 Covance: Historical Revenue ($bn) by Business Segment, 2009-2012

Table 5.11 Covance: Early Development Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.12 Selected Cyprotex Partnerships, 2013

Table 5.13 Cyprotex: Historical Revenue ($m) by Region, 2010-2012

Table 5.14 Cyprotex: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.15 Domainex's Collaborations and Partnerships, 2013

Table 5.16 Evotec: Historical Revenue ($m, AGR %), 2008-2012

Table 5.17 Evotec Action Plan 2016: Leadership in Drug Discovery Solutions

Table 5.18 Evotec: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 5.19 Galapagos Pipeline Projects and Development stages, 2013

Table 5.20 Galapagos: Historical operating Income ($m) by Business Sector, 2011 and 2012

Table 5.21 Genscript: Services Offered and Descriptions, 2013

Table 5.22 Quintiles: Historical Revenue ($bn, AGR %), 2008-2012

Table 5.23 Quintiles: Revenue Forecast ($bn, AGR %, CAGR%), 2012-2024

Table 5.24 WuXi AppTec: Pharmaceutical Laboratory Services and Descriptions, 2013

Table 5.25 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012

Table 5.26 WuXi AppTec: Laboratory Services Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

Table 6.1 Drug Discovery Outsourcing: Market Drivers, 2014-2024

Table 6.2 Drug Discovery Outsourcing: Market Restraints, 2014-2024

Table 6.3 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2014-2024

Table 6.4 NIH Biomarker Definitions, 2013

Table 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn, CAGR%): 2012, 2017, 2020, 2024

Table 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2020, 2024

Table 8.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2020, 2024

List of Figures

Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013

Figure 2.2 Typical Stages of the Drug Development Cycle

Figure 3.1 PhRMA's Historical Estimate for its Member's R&D Spending ($bn)

Figure 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Sector, 2012 and 2013

Figure 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2017

Figure 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2017-2024

Figure 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017

Figure 3.6 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2017-2024

Figure 3.7 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2024

Figure 3.8 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2024

Figure 3.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2012

Figure 3.10 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2017

Figure 3.11 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2024

Figure 3.12 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 3.13 The Biology Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 3.14 An Overview of ADMET Screening in Drug Discovery

Figure 3.15 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 3.16 Typical Steps in the Lead Screening Process

Figure 3.17 The Global Lead Identification and Screening Market: Revenue Forecast ($bn), 2012-2024

Figure 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Region, 2012

Figure 4.2 US, EU5, and Japan Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.3 China, India, South Korea, Brazil, and Russia Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017

Figure 4.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2017-2024

Figure 4.6 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2024

Figure 4.7 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012

Figure 4.8 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2017

Figure 4.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2024

Figure 4.10 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.11 Germany, UK, France, Italy, and Spain Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.12 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2024

Figure 4.13 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012

Figure 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.15 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.16 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.17 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.18 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024

Figure 4.19 Japanese Over-65 Population and Forecast (%): 2010, 2013, 2035, 2060

Figure 4.20 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.21 Chinese Demographics: Over 65 Population and Forecast (millions), 1950, 2010, 2050

Figure 4.22 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.23 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.24 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.25 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024

Figure 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2008-2012

Figure 5.2 Albany Molecular Research (AMRI): Revenue Forecast ($m), 2012-2024

Figure 5.3 Charles River: Historical Revenue ($m), 2010-2012

Figure 5.4 Charles River: Historical Revenue ($m) by Segment, 2012

Figure 5.5 Charles River: Revenue Forecast ($m), 2012-2024

Figure 5.6 Covance: Historic Revenue ($bn), 2009-2012

Figure 5.7 Covance: Revenue ($bn) by Segment, 2012

Figure 5.8 Covance: Early Development Revenue Forecast ($m), 2012-2024

Figure 5.9 Cyprotex: Historical Revenue ($m), 2010-2012

Figure 5.10 Cyprotex: Revenue Shares (%) by Region, 2012

Figure 5.11 Cyprotex: Revenue Forecast ($m), 2012-2024

Figure 5.12 Evotec: Historical Revenue ($m), 2008-2012

Figure 5.13 Evotec: Revenue Forecast ($m), 2012-2024

Figure 5.14 Galapagos: Revenue Share (%) by Business Sector, 2012

Figure 5.15 Quintiles: Historical Revenue ($bn), 2008-2012

Figure 5.16 Quintiles: Revenue Forecast ($bn), 2012-2024

Figure 5.17 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012

Figure 5.18 WuXi AppTec: Laboratory Services Revenue Forecast ($m), 2012-2024

Figure 6.1 Porter's Five Force Analysis of the Drug Discovery Outsourcing Market, 2013

Figure 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn): 2012, 2017, 2020, 2024

Figure 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017, 2020, 2024

Figure 8.3 Global Over-60 Population Forecast (%): 1950, 2009, 2050

Figure 8.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017, 2020, 2024

Companies Listed

Abbott

Accugenix

Advion Bioanalytical

Albany Molecular Research Inc (AMRI)

Andromeda Biotech (Teva)

Apredica (Cyprotex)

Aptuit

Argenta (Galapagos)

AstraZeneca

Bayer

Behrman Capital

BioCity

BioDuro (PPD)

BioFocus (Galapagos)

Biopontis Alliance

Boehringer Ingelheim

Bristol-Myers Squibb

Caprion Proteomics

Carlyle Group

Catalent Pharma Solutions

Cerebricon (Charles River)

Charles River Laboratories

ChemBridge

ChemDiv

Compound Focus (Evotec)

Covance

Crucell

Cyprotex

Discovery Partners International

Domainex

Dow AgroSciences

Dow Chemical Company

Elan

Eli Lilly

Evotec

Fidelity Growth Partners India (FGPI)

Fidelta (Galapagos)

Furiex Pharmaceuticals

Galapagos

Genentech

GenScript

GlaxoSmithKline (GSK)

Glycoform

Great Lakes Chemical Corporation

Hangzhou Tigermed Consulting

Hellman & Friedman

Hypha Discovery

i3 Research (inVentiv Health)

ICON

Inpharmatica

InSphero

InVentiv Health

Johnson & Johnson (J&J)

Janssen Pharmaceutical Group

Kinaxo

Knopp Biosciences

ICON

Immatics

JOINN Laboratories

Laurus Labs

Lonza

MAB Discovery

MedImmune

Merck & Co.

Microsoft

Midwest BioResearch (WIL Research)

Millipore

Novartis

Ono Pharmaceutical

Oxford Asymmetry International

Parexel

Peking Union Lawke Biomedical Development Limited (PUL)

Pfizer

Myriad RBM

Pharmaceutical Product Development (PPD)

Pharmidex

PharmaNet Development Group (inVentiv Health)

Pharminox

Piedmont Research Center (Charles River)

PRA International

ProSkelia

ProStrakan

Proteome Sciences

Proteros Biostructures GmbH (Proteros)

ProtonMedia

Quintiles

Ricerca Biosciences (WIL Research)

Roche

Samsung

Sanofi

Sareum Holdings Plc

Servier

ShangPharma Corporation

Shionogi

Sirius Analytical

Solvo Biotechnology

Swiss Pharma Contract

Sygnature Discovery

SYNthesis Med Chem

Taijitu Biologics

Takeda

Teva

The Dow Chemical Company

Tibotec

TRAC Microbiology

TransGenic

UCB

VitualScopics

WIL Research Laboratories

WuXi AppTec

WuXi PharmaTech

Other Organisations Mentioned in This Report

American Cancer Society

Associacao Brasileira de CROs (Abracro)

Beijing Genomics Institute

Bundesverband Medizinischer Auftragsinstitute (BVMA)

CHDI Foundation

Dundee University

Food and Drug Administration (US FDA)

Indiana Clinical and Translational Sciences Institute (CTSI)

Johns Hopkins University

Massachusetts General Hospital

National Institute for Population and Social Security Research (IPSS)

National Institutes of Health (NIH)

Pharmaceutical Research and Manufacturers of America (PhRMA)

Russian Corporation of Nanotechnologies

Southwestern Medical Center

The European Innovative Medicine Initiative (IMI)

The European CRO Federation (EUCROF)

The Institute of Cancer Research

The Organization for Economic Cooperation and Development (OECD)

University of Manchester

University of North Carolina

Wellcome Trust

World Health Information Science Consultants (WHISCON)

World Health Organization (WHO)

World Trade Organization (WTO)

To order this report: Drug Discovery Outsourcing: World Market Forecast 2014-2024 & Future Prospects for Leading Companies http://www.reportlinker.com/p02041940/Drug-Discovery-Outsourcing-World-Market-Forecast-2014-2024--Future-Prospects-for-Leading-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development__

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Whether they’re located in a public, private, or hybrid cloud environment, cloud technologies are constantly evolving. While the innovation is exciting, the end mission of delivering business value and rapidly producing incremental product features is paramount. In his session at @DevOpsSummit at 19th Cloud Expo, Kiran Chitturi, CTO Architect at Sungard AS, will discuss DevOps culture, its evolution of frameworks and technologies, and how it is achieving maturity. He will also cover various st...
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
In his session at @ThingsExpo, Kausik Sridharabalan, founder and CTO of Pulzze Systems, Inc., will focus on key challenges in building an Internet of Things solution infrastructure. He will shed light on efficient ways of defining interactions within IoT solutions, leading to cost and time reduction. He will also introduce ways to handle data and how one can develop IoT solutions that are lean, flexible and configurable, thus making IoT infrastructure agile and scalable.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). Download Slide Deck: ▸ Here In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discusse...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
Internet of @ThingsExpo has announced today that Chris Matthieu has been named tech chair of Internet of @ThingsExpo 2016 Silicon Valley. The 6thInternet of @ThingsExpo will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.